<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
    
    
    
  
  

  <meta name="author" content="Benjamin Skov Kaas-Hansen">

  
  
  
    
  
  <meta name="description" content=" **Importance**: While the beneficial effects of medications are numerous, drug-drug interactions may lead to adverse drug reactions that are preventable causes of morbidity and mortality. &lt;br /&gt;
**Objective**: To quantify the prevalence of potential drug-drug interactions in drug prescriptions at Danish hospitals, estimate the risk of adverse outcomes associated with discouraged drug combinations, and highlight the patient types (defined by the primary diagnosis of the admission) that appear to be more affected. &lt;br /&gt;
**Design**: Cross-sectional (descriptive part) and cohort study (adverse outcomes part). &lt;br /&gt;
**Setting**: Hospital electronic health records from two Danish regions (approx. 2.5 million people) from January 2008 through June 2016. &lt;br /&gt;
**Participants**: Inpatients receiving two or more medications during their admission. &lt;br /&gt;
**Exposure**: Concomitant prescriptions of potentially interacting drugs as per the Danish Drug Interaction Database. &lt;br /&gt;
**Main outcome and measure**: Descriptive part: prevalence of potential drug-drug interactions in general and discouraged drug pairs in particular during admissions. Adverse outcomes part: post-discharge all-cause mortality rate, readmission rate and length-of-stay. &lt;br /&gt;
**Results**: Among 2,886,227 hospital admissions (945,475 patients; median age 62 years [IQR: 41-74]; 54% female; median number of drugs 7 [IQR: 4-11]), patients in 1,836,170 admissions were exposed to at least one potential drug-drug interaction (659,525 patients; median age 65 years [IQR: 49-77]; 54% female; median number of drugs 9 [IQR: 6-13]), and in 27,605 admissions to a discouraged drug pair (18,192 patients; median age 68 years [IQR: 58-77]; female 46%; median number of drugs 16 [IQR: 11-22]). Meropenem-valproic acid (HR: 1.5, 95% CI: 1.1–1.9), domperidone-fluconazole (HR: 2.5, 95% CI: 2.1–3.1), imipramine-terbinafine (HR: 3.8, 95% CI: 1.2–12), agomelatine-ciprofloxacin (HR: 2.6, 95% CI: 1.3–5.5), clarithromycin-quetiapine (HR: 1.7, 95% CI: 1.1–2.7), and piroxicam-warfarin (HR: 3.4, 95% CI: 1–11.4) were associated with elevated mortality. Confidence interval bounds of pairs associated with readmission were close to 1; length-of-stay results were inconclusive. &lt;br /&gt;
**Conclusions and Relevance**: Well-described potential drug-drug interactions are still missed and alerts at point of prescription may reduce the risk of harming patients; prescribing clinicians should be alert when using strong inhibitor/inducer drugs (i.e. clarithromycin, valproic acid, terbinafine) and prevalent anticoagulants (i.e. warfarin and NSAIDs) due to their great potential for dangerous interactions. The most prominent CYP isoenzyme involved in mortality and readmission rates was 3A4. ">

  
  <link rel="alternate" hreflang="en-us" href="/publication/preprint-ddimark/">

  


  
  
  
  <meta name="theme-color" content="hsl(339, 90%, 68%)">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light" disabled>
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark">
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  




  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/publication/preprint-ddimark/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="twitter:site" content="@benskov">
  <meta property="twitter:creator" content="@benskov">
  
  <meta property="og:site_name" content="Benjamin Skov Kaas-Hansen">
  <meta property="og:url" content="/publication/preprint-ddimark/">
  <meta property="og:title" content="Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes | Benjamin Skov Kaas-Hansen">
  <meta property="og:description" content=" **Importance**: While the beneficial effects of medications are numerous, drug-drug interactions may lead to adverse drug reactions that are preventable causes of morbidity and mortality. &lt;br /&gt;
**Objective**: To quantify the prevalence of potential drug-drug interactions in drug prescriptions at Danish hospitals, estimate the risk of adverse outcomes associated with discouraged drug combinations, and highlight the patient types (defined by the primary diagnosis of the admission) that appear to be more affected. &lt;br /&gt;
**Design**: Cross-sectional (descriptive part) and cohort study (adverse outcomes part). &lt;br /&gt;
**Setting**: Hospital electronic health records from two Danish regions (approx. 2.5 million people) from January 2008 through June 2016. &lt;br /&gt;
**Participants**: Inpatients receiving two or more medications during their admission. &lt;br /&gt;
**Exposure**: Concomitant prescriptions of potentially interacting drugs as per the Danish Drug Interaction Database. &lt;br /&gt;
**Main outcome and measure**: Descriptive part: prevalence of potential drug-drug interactions in general and discouraged drug pairs in particular during admissions. Adverse outcomes part: post-discharge all-cause mortality rate, readmission rate and length-of-stay. &lt;br /&gt;
**Results**: Among 2,886,227 hospital admissions (945,475 patients; median age 62 years [IQR: 41-74]; 54% female; median number of drugs 7 [IQR: 4-11]), patients in 1,836,170 admissions were exposed to at least one potential drug-drug interaction (659,525 patients; median age 65 years [IQR: 49-77]; 54% female; median number of drugs 9 [IQR: 6-13]), and in 27,605 admissions to a discouraged drug pair (18,192 patients; median age 68 years [IQR: 58-77]; female 46%; median number of drugs 16 [IQR: 11-22]). Meropenem-valproic acid (HR: 1.5, 95% CI: 1.1–1.9), domperidone-fluconazole (HR: 2.5, 95% CI: 2.1–3.1), imipramine-terbinafine (HR: 3.8, 95% CI: 1.2–12), agomelatine-ciprofloxacin (HR: 2.6, 95% CI: 1.3–5.5), clarithromycin-quetiapine (HR: 1.7, 95% CI: 1.1–2.7), and piroxicam-warfarin (HR: 3.4, 95% CI: 1–11.4) were associated with elevated mortality. Confidence interval bounds of pairs associated with readmission were close to 1; length-of-stay results were inconclusive. &lt;br /&gt;
**Conclusions and Relevance**: Well-described potential drug-drug interactions are still missed and alerts at point of prescription may reduce the risk of harming patients; prescribing clinicians should be alert when using strong inhibitor/inducer drugs (i.e. clarithromycin, valproic acid, terbinafine) and prevalent anticoagulants (i.e. warfarin and NSAIDs) due to their great potential for dangerous interactions. The most prominent CYP isoenzyme involved in mortality and readmission rates was 3A4. "><meta property="og:image" content="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2021-06-02T00:00:00&#43;00:00">
    
    <meta property="article:modified_time" content="2021-06-02T00:00:00&#43;00:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "/publication/preprint-ddimark/"
  },
  "headline": "Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes",
  
  "datePublished": "2021-06-02T00:00:00Z",
  "dateModified": "2021-06-02T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Benjamin Skov Kaas-Hansen"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Benjamin Skov Kaas-Hansen",
    "logo": {
      "@type": "ImageObject",
      "url": "/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_2.png"
    }
  },
  "description": " **Importance**: While the beneficial effects of medications are numerous, drug-drug interactions may lead to adverse drug reactions that are preventable causes of morbidity and mortality. \u003cbr /\u003e\n**Objective**: To quantify the prevalence of potential drug-drug interactions in drug prescriptions at Danish hospitals, estimate the risk of adverse outcomes associated with discouraged drug combinations, and highlight the patient types (defined by the primary diagnosis of the admission) that appear to be more affected. \u003cbr /\u003e\n**Design**: Cross-sectional (descriptive part) and cohort study (adverse outcomes part). \u003cbr /\u003e\n**Setting**: Hospital electronic health records from two Danish regions (approx. 2.5 million people) from January 2008 through June 2016. \u003cbr /\u003e\n**Participants**: Inpatients receiving two or more medications during their admission. \u003cbr /\u003e\n**Exposure**: Concomitant prescriptions of potentially interacting drugs as per the Danish Drug Interaction Database. \u003cbr /\u003e\n**Main outcome and measure**: Descriptive part: prevalence of potential drug-drug interactions in general and discouraged drug pairs in particular during admissions. Adverse outcomes part: post-discharge all-cause mortality rate, readmission rate and length-of-stay. \u003cbr /\u003e\n**Results**: Among 2,886,227 hospital admissions (945,475 patients; median age 62 years [IQR: 41-74]; 54% female; median number of drugs 7 [IQR: 4-11]), patients in 1,836,170 admissions were exposed to at least one potential drug-drug interaction (659,525 patients; median age 65 years [IQR: 49-77]; 54% female; median number of drugs 9 [IQR: 6-13]), and in 27,605 admissions to a discouraged drug pair (18,192 patients; median age 68 years [IQR: 58-77]; female 46%; median number of drugs 16 [IQR: 11-22]). Meropenem-valproic acid (HR: 1.5, 95% CI: 1.1–1.9), domperidone-fluconazole (HR: 2.5, 95% CI: 2.1–3.1), imipramine-terbinafine (HR: 3.8, 95% CI: 1.2–12), agomelatine-ciprofloxacin (HR: 2.6, 95% CI: 1.3–5.5), clarithromycin-quetiapine (HR: 1.7, 95% CI: 1.1–2.7), and piroxicam-warfarin (HR: 3.4, 95% CI: 1–11.4) were associated with elevated mortality. Confidence interval bounds of pairs associated with readmission were close to 1; length-of-stay results were inconclusive. \u003cbr /\u003e\n**Conclusions and Relevance**: Well-described potential drug-drug interactions are still missed and alerts at point of prescription may reduce the risk of harming patients; prescribing clinicians should be alert when using strong inhibitor/inducer drugs (i.e. clarithromycin, valproic acid, terbinafine) and prevalent anticoagulants (i.e. warfarin and NSAIDs) due to their great potential for dangerous interactions. The most prominent CYP isoenzyme involved in mortality and readmission rates was 3A4. "
}
</script>

  

  


  


  





  <title>Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes | Benjamin Skov Kaas-Hansen</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="dark">

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">Benjamin Skov Kaas-Hansen</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">Benjamin Skov Kaas-Hansen</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-end" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#publications"><span>Publications</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#talks_teaching"><span>Talks and teaching</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      
      <li class="nav-item dropdown theme-dropdown">
        <a href="#" class="nav-link js-theme-selector" data-toggle="dropdown" aria-haspopup="true">
          <i class="fas fa-palette" aria-hidden="true"></i>
        </a>
        <div class="dropdown-menu">
          <a href="#" class="dropdown-item js-set-theme-light">
            <span>Light</span>
          </a>
          <a href="#" class="dropdown-item js-set-theme-dark">
            <span>Dark</span>
          </a>
          <a href="#" class="dropdown-item js-set-theme-auto">
            <span>Automatic</span>
          </a>
        </div>
      </li>
      

      

    </ul>

  </div>
</nav>


  <div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes</h1>

  

  
    


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    June 2021
  </span>
  

  

  

  
  
  

  
  

</div>

    











  



<div class="btn-links mb-3">
  
  








  
    
  



<a class="btn btn-outline-primary my-1 mr-1" href="https://www.medrxiv.org/content/10.1101/2021.05.27.21257764v1.full.pdf" target="_blank" rel="noopener">
  PDF
</a>



<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/preprint-ddimark/cite.bib">
  Cite
</button>













<a class="btn btn-outline-primary my-1 mr-1" href="https://doi.org/10.1101/2021.05.27.21257764" target="_blank" rel="noopener">
  DOI
</a>


  
  
  
    
  
  
  
  
  
    
    
      
    
  
  <a class="btn btn-outline-primary my-1 mr-1" href="/publication/article-ddimark" >
    
    Published article
  </a>


</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract"><strong>Importance</strong>: While the beneficial effects of medications are numerous, drug-drug interactions may lead to adverse drug reactions that are preventable causes of morbidity and mortality. <br />
<strong>Objective</strong>: To quantify the prevalence of potential drug-drug interactions in drug prescriptions at Danish hospitals, estimate the risk of adverse outcomes associated with discouraged drug combinations, and highlight the patient types (defined by the primary diagnosis of the admission) that appear to be more affected. <br />
<strong>Design</strong>: Cross-sectional (descriptive part) and cohort study (adverse outcomes part). <br />
<strong>Setting</strong>: Hospital electronic health records from two Danish regions (approx. 2.5 million people) from January 2008 through June 2016. <br />
<strong>Participants</strong>: Inpatients receiving two or more medications during their admission. <br />
<strong>Exposure</strong>: Concomitant prescriptions of potentially interacting drugs as per the Danish Drug Interaction Database. <br />
<strong>Main outcome and measure</strong>: Descriptive part: prevalence of potential drug-drug interactions in general and discouraged drug pairs in particular during admissions. Adverse outcomes part: post-discharge all-cause mortality rate, readmission rate and length-of-stay. <br />
<strong>Results</strong>: Among 2,886,227 hospital admissions (945,475 patients; median age 62 years [IQR: 41-74]; 54% female; median number of drugs 7 [IQR: 4-11]), patients in 1,836,170 admissions were exposed to at least one potential drug-drug interaction (659,525 patients; median age 65 years [IQR: 49-77]; 54% female; median number of drugs 9 [IQR: 6-13]), and in 27,605 admissions to a discouraged drug pair (18,192 patients; median age 68 years [IQR: 58-77]; female 46%; median number of drugs 16 [IQR: 11-22]). Meropenem-valproic acid (HR: 1.5, 95% CI: 1.1–1.9), domperidone-fluconazole (HR: 2.5, 95% CI: 2.1–3.1), imipramine-terbinafine (HR: 3.8, 95% CI: 1.2–12), agomelatine-ciprofloxacin (HR: 2.6, 95% CI: 1.3–5.5), clarithromycin-quetiapine (HR: 1.7, 95% CI: 1.1–2.7), and piroxicam-warfarin (HR: 3.4, 95% CI: 1–11.4) were associated with elevated mortality. Confidence interval bounds of pairs associated with readmission were close to 1; length-of-stay results were inconclusive. <br />
<strong>Conclusions and Relevance</strong>: Well-described potential drug-drug interactions are still missed and alerts at point of prescription may reduce the risk of harming patients; prescribing clinicians should be alert when using strong inhibitor/inducer drugs (i.e. clarithromycin, valproic acid, terbinafine) and prevalent anticoagulants (i.e. warfarin and NSAIDs) due to their great potential for dangerous interactions. The most prominent CYP isoenzyme involved in mortality and readmission rates was 3A4.</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9">medRxiv</div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    





<div class="article-tags">
  
  <a class="badge badge-light" href="/tag/first-author/">First author</a>
  
</div>














  
  





  
    
    
    
      
    
    
    
    <div class="media author-card content-widget-hr">
      
        
        <img class="avatar mr-3 avatar-circle" src="/author/benjamin-skov-kaas-hansen/ben_avatar_hu94d5b671a33123f312d6f8d093b30631_902385_270x270_fill_lanczos_center_2.png" alt="Benjamin Skov Kaas-Hansen">
      

      <div class="media-body">
        <h5 class="card-title"><a href="/">Benjamin Skov Kaas-Hansen</a></h5>
        <h6 class="card-subtitle">MD, MSc, PhD candidate</h6>
        <p class="card-text">MD, MSc en epi-biostats, pursuing a PhD in clinical pharmacology and data science. Research interests include causal inference, Bayesian methods, data standardisation and visualiation, and actionable machine learning.</p>
        <ul class="network-icon" aria-hidden="true">
  
    
    
    
      
    
    
    
    
    
    <li>
      <a href="mailto:epiben@hey.com" >
        <i class="fas fa-envelope"></i>
      </a>
    </li>
  
    
    
    
      
    
    
    
    
    
      
    
    <li>
      <a href="https://github.com/epiben" target="_blank" rel="noopener">
        <i class="fab fa-github"></i>
      </a>
    </li>
  
    
    
    
    
    
    
    
      
    
    <li>
      <a href="https://scholar.google.co.uk/citations?user=zn9W12AAAAAJ" target="_blank" rel="noopener">
        <i class="ai ai-google-scholar"></i>
      </a>
    </li>
  
</ul>

      </div>
    </div>
  












  
  



  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = true;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.37431be2d92d7fb0160054761ab79602.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/privacy/">Privacy Policy</a>
    
    
       &middot; 
      <a href="/terms/">Terms</a>
    
  </p>
  

  <p class="powered-by">
    

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
